A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects

NCT05506540 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: ENN0403 1mg
DRUG: ENN0403 4mg
DRUG: ENN0403 10mg
DRUG: ENN0403 20mg
DRUG: ENN0403 30mg
DRUG: ENN0403 20mg (Fed)
DRUG: ENN0403 6mg QD X 14 Days
DRUG: ENN0403 12mg QD X 14 Days
DRUG: ENN0403 20mg QD X 14 Days
DRUG: Placebo

Sponsor

EnnovaBio